PRMT5 and mantle cell lymphoma: Our collaborative group has developed a series of first-in-class small molecule inhibitors of PRMT5 (HLCL65, C220, PRT382, PRT543) demonstrating antitumor activity in MCL, DLBCL, HTLV-1 induced adult T-cell leukemia/lymphoma, acute myeloid leukemia (AML), and glioblastoma cells [28,33,34,40,41].